An Open Trial to Assess the Tolerability of AVANZ Mite Mix Immunotherapy

Inclusion Criteria: * Male and female patients 18-65 years of age. * A clinical history of HDM induced allergic rhinoconjunctivitis with or without asthma at least one year prior to trial entry. * Positive SPT to Dermatophagoides pteronyssinus (Der pte) or Dermatophagoides farinae (Der far) (wheal diameter ≥ 3 mm). * A positive specific IgE against Der pte or Der far (≥Class 2; ≥0.70 KU/L) documenting in the last 5 years. Exclusion Criteria: * FEV1 \< 70% of predicted value at screening after adequate pharmacologic treatment. * Uncontrolled or severe asthma. * A clinically relevant history of symptomatic perennial allergic rhinitis and/or conjunctivitis caused by an allergen, to which the subject is regularly exposed and sensitized. * History of severe asthma exacerbation or emergency room visit or admission for asthma in the previous 12 months. * At screening, current symptoms of, or treatment for, upper respiratory tract infection, acute sinusitis, acute otitis media or other relevant infection (serous otitis media is not an exclusion criterion). * Treatment with parenteral corticosteroids, oral corticosteroids or anti-IgE in the previous 3 months or during the study (except for steroids if needed as rescue medication). Please, see Table 4. * Currently treated with angiotensin converting enzyme (ACE) inhibitors, tricyclic antidepressants, β-blockers, mono amine oxidase inhibitors (MAOIs) and any other drug containing alum (e.g. antacids) taken on a daily basis. * Previous treatment by other allergen concomitant IT or immunotherapy with HDM extracts within the previous 5 years (initiation of subcutaneous immunotherapy is acceptable if treatment has been discontinued before reaching maintenance dose; for SLIT 3 months in the last 5 years is accepted). * History of anaphylactic shock due to e.g. food, insect venom, exercise or drug. * History of severe and recurrent angioedema. * Any contraindication according to the Investigator Brochure (IB). * Use of an investigational drug within 30 days prior to screening.